Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6875—Nucleoproteins
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value
  • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

• the present invention relates to DNA-barcoded recombinant nucleosomes and polynucleosomes that have been engineered for use as spike-in controls for chromatin accessibility assays, chromatin mapping assays, e.g., using tethered enzymes, as well as other chromatin assays.
• the invention further relates to methods of using the engineered DNA- barcoded recombinant nucleosomes in chromatin accessibility assays, chromatin mapping assays, as well as other chromatin assays.
• Chromatin structure drives the regulation of gene transcription by controlling the accessibility of regulatory machinery (e.g. transcription factors) to engage DNA (Stavreva and Hager 2015). This process is controlled in part by the local positioning of nucleosomes on the DNA template (Bai and Morozov 2010). So-called‘open’ regions are largely devoid of nucleosomes and often associated with poised or actively transcribed genes (Tsompana and Buck 2014). In contrast, genomic regions with high nucleosome density are often transcriptionally inactive, since this conformation restricts access by the regulatory machinery. As a result, chromatin accessibility is a hallmark of active gene status that tightly tracks cellular differentiation and identity (Natarajan, Yardimci et al.
• ATAC-seq uses a Tn5 transposase that preferentially targets and delivers its sequence adaptor payload into accessible regions (Buenrostro, Wu et al. 2015). This method has quickly garnered field adoption due to its speed and low cell requirements.
• ATAC-seq assays can be performed in a single day and have recently been developed for single cell applications, which would be of great utility for clinical assays (Buenrostro, Giresi et al. 2013).
• ATAC-seq is incompatible with fixed tissues and often needs careful optimization.
• the approach requires high sequencing depth (100-150 million reads per sample since >50% of reads come from mitochondrial DNA and are discarded) and single cell data is very sparse (similar to scDNase samples above).
• Histone PTMs are commonly mapped using Chromatin ImmunoPrecipitation (ChIP)
• ChIP ChIP is hampered by poor yields and low accuracy / reliability. Such limitations stem from the use of poorly validated“ChIP-grade” antibodies (Bock, Dhayalan et al. 2011,
• New‘chromatin tethering’ methods affix enzymes to specific genomic regions, resulting in labeling/release, and selective analysis of target material (e.g . DamID, ChIC,
• CUT&RUN, and CUT&Tag (Klein and Hainer 2019).
• CUT&RUN and ChIC use a factor- specific antibody to tether a fusion protein of protein A and micrococcal nuclease (pA-
• pA-MNase provides a cleavage tethering system for antibodies to any PTM, transcription factor, or chromatin protein of interest.
• the CUT&RUN protocol is further streamlined by using a solid support to adhere cells (or nuclei) to lectin-coated WO 2020/132388 PCT/US2019/067735 magnetic beads, generating reliable genomic mapping data using as few as 100 cells (Skene,
• CUT&Tag uses antibodies to bind chromatin proteins in situ , and then tethers a protein A, protein G/hyperactive Tn5 transposase (pAG-Tn5) fusion to these sites. Upon controlled activation, the Tn5 selectively fragments and integrates adapter sequences at the genomic sites. The tagged target DNA is then amplified and sequenced, thereby bypassing several library preparation steps, saving time (total workflow time of ⁇ 1 day) and eliminating a source of experimental bias. Importantly, CUT&Tag assays generate highly reliable data similar to CUT&RUN. Further, the high sensitivity (i. e. , signal-to-noise;
• Spike-in controls are needed for all genome-wide analyses as they i) are essential for normalizing samples to enable cross-sample comparisons and ii) can be used as internal controls to monitor assay variation (e.g., antibody specificity / efficiency or technical variability).
• DNA-barcoded recombinant nucleosomes carrying histone PTMs were recently developed as spike-in controls to standardize ChIP methodology (named Internally calibrated
• ICeChIP DNA-barcoded designer nucleosomes (dNucs) carrying specific histone PTMs as internal control standards to monitor antibody performance (i.e., specificity/efficiency and technical variability in situ ) and for quantitative sample normalization.
• DNA-barcoded nucleosomes panels comprising one or more nucleosomes carrying unique PTMs at a single or range of concentrations(s), are spiked into samples before or after chromatin fragmentation.
• the resulting nucleosome mix (dNuc and cell derived) is immunoprecipitated with a bead- immobilized antibody specific for the PTM of interest.
• qPCR DNA-barcoded designer nucleosomes
• dNucs serve as direct performance reagents/calibrators as WO 2020/132388 PCT/US2019/067735 they mimic the endogenous antibody target (modified mononucleosomes), and are subject to the same sources of variability experienced by the sample chromatin during ChIP processing.
• DNA-barcoded recombinant nucleosomes have also been applied to develop medium-throughput chromatin binding ([19]; WO 2013/184930) and remodeling [20] assays.
• DNA-barcoded nucleosomes are comprised of synthetic DNA template(s) wrapped to a uniquely (unmodified histone octamer.
• Current “ChIP-compatible” DNA-barcoded recombinant nucleosomes are incompatible with a chromatin accessibility assays (e.g., MNase-seq or ATAC-seq) and immunotethering approaches (e.g., CUT&RUN or CUT&Tag). Specifically, they do not contain the necessary means for immobilization or sufficient linker DNA sequence for enzyme targeting (e.g., MNase or Tn5).
• the present invention relates to DNA-barcoded recombinant nucleosomes and polynucleosomes that have been engineered for use as spike-in controls for chromatin accessibility assays, chromatin mapping assays (e.g. , using tethered enzymes), as well as other chromatin assays.
• the invention further relates to methods of using the engineered
• nucleosome spike-in controls may be used in assays that contain multiple cells (i. e. , bulk analysis), single cells (i.e., single cell analysis), or cell-free nucleosomes. These spike- in controls may be used for several major applications, including without limitation assay optimization, technical variability monitoring, quantitative sample normalization, and antibody performance testing (for antibody-based assays, e.g. , antibody target specificity and capture efficiency).
• DNA barcode is protected from modifying enzymes (such as MNase or Tn5) as it is located within the 147 bp nucleosome positioning sequence. This is ideal for ChIP assays as they can be used in native
• ChIP workflows that i) require nucleosomes to be soluble and ii) use MNase to digest chromatin into mononucleosomes prior to IP.
• Current nucleosome spike-ins also lack a binding moiety for assays that use a solid support.
• the present invention describes novel DNA-barcoded nucleosomes comprising a modified nucleosome positioning sequence that contains linker DNA to allow for the targeting of enzymes that are commonly used in chromatin accessibility assays (e.g.
• nucleosome spike- ins may be further modified to contain a binding moiety (e.g. , a DNA biotin-tag) for immobilization.
• a binding moiety e.g. , a DNA biotin-tag
• modified DNA-barcoded dNucs will serve as direct calibrators because they mimic the endogenous target (i.e., chromatin) and are subject to the same ' sources of variability experienced by the sample chromatin during processing.
• nucleosome comprising:
• a a protein octamer, containing two copies each of histones H2A, H2B, H3, and H4, and optionally, linker histone HI ;
• a DNA molecule comprising:
• a DNA barcode indicative of the identity and/or concentration of a nucleosome feature
• iii a nuclease or transposase recognition sequence
• nucleosome feature is none, one, or more of the histones comprising a post-translational modification or a mutation and/or a histone variant and/or the DNA molecule comprising a post-transcriptional modification.
• the nucleosome further comprises:
• binding member linked to the DNA molecule, wherein the binding member specifically binds to a binding partner.
• the invention further relates to a panel of the nucleosomes of the invention, wherein the panel comprises at least two nucleosomes comprising different nucleosome features.
• Another aspect of the invention relates to a polynucleosome comprising:
• a DNA molecule comprising:
• a DNA barcode indicative of the identity and/or concentration of a nucleosome feature
• nucleosome feature is none, one, or more of the histones comprising a post-translational modification or a mutation and/or a histone variant and/or the DNA molecule comprising a post-transcriptional modification.
• the polynucleosome further comprises:
• binding member linked to the DNA molecule, wherein the binding member specifically binds to a binding partner.
• An additional aspect of the invention relates to an array comprising the
• a further aspect of the invention relates to a pool of the array of the invention, wherein each array comprises a nucleosome feature.
• Another aspect of the invention relates to a bead comprising a binding partner to the binding member of the nucleosome, panel, polynucleosome, array, or pool of the invention, wherein the bead is bound to the nucleosome, panel, polynucleosome, array, or pool.
• An additional aspect of the invention relates to a kit comprising the nucleosome, panel, polynucleosome, array, pool, or bead of the invention.
• a further aspect of the invention relates to a method for chromatin mapping or determining chromatin accessibility, wherein the improvement is the use of the nucleosome, panel, polynucleosome, array, pool, or bead of the invention in the assay as a spike-in control.
• the methods may be carried out with or without using a solid support.
• Another aspect of the invention relates to a method for mapping chromatin using tethered enzymes, comprising the steps of:
• nucleosome, panel, polynucleosome, array, or pool of the invention to the permeabilized cell, nucleus, organelle, or tissue of a);
• nuclease or transposase allowing the nuclease or transposase to cleave and/or tag DNA in the cell, nucleus, organelle, or tissue and the nuclease or transposase recognition sequence in the nucleosome, panel, polynucleosome, array, or pool;
• nucleosome feature is none, one, or more of the histones comprising a post- translational modification or a mutation and/or a histone variant and/or the DNA molecule comprising a post-transcriptional modification.
• Another aspect of the invention relates to a method for mapping chromatin using tethered enzymes, comprising the steps of:
• nuclease or transposase cleave and/or tag DNA in the cell, nucleus, organelle, tissue, or cell-free nucleosome and the nuclease or transposase recognition sequence in the nucleosome, panel, polynucleosome, array, or pool;
• nucleosome feature is none, one, or more of the histones comprising a post- translational modification or a mutation and/or a histone variant and/or the DNA molecule comprising a post-transcriptional modification.
• An additional aspect of the invention relates to a method for determining chromatin accessibility, comprising the steps of:
• nucleosome, panel, polynucleosome, array, or pool of the invention to the permeabilized cell, nucleus, organelle, or tissue of a);
• An additional aspect of the invention relates to a method for determining chromatin accessibility, comprising the steps of:
• transposase allowing the transposase to tag DNA in the cell, nucleus, organelle, tissue, or cell- free nucleosome and in the nucleosome, panel, polynucleosome, array, or pool; and f) identifying the tagged DNA;
• a further aspect of the invention relates to a method for detecting and quantitating the presence of an epigenetic modification or mutation in chromatin, comprising using the methods of the invention.
• Another aspect of the invention relates to a method for determining and quantitating the epigenetic or mutation status of chromatin in a subject having a disease or disorder, comprising using the methods of the invention.
• An additional aspect of the invention relates to a method for monitoring changes in epigenetic or mutation status of chromatin over time in a subject, comprising using the methods of the invention.
• a further aspect of the invention relates to a method for measuring on-target activity of an epigenetic-targeting drug, comprising using the methods of the invention.
• Another aspect of the invention relates to a method for monitoring the effectiveness of an epigenetic therapy or mutation therapy in a subject having a disease or disorder associated with epigenetic modifications or mutations, comprising using the methods of the invention.
• An additional aspect of the invention relates to a method for selecting a suitable treatment for a subject having a disease or disorder associated with epigenetic modifications or mutations based on the epigenetic or mutation status of chromatin in the subject, comprising using the methods of the invention.
• a further aspect of the invention relates to a method for determining a prognosis for a subject having a disease or disorder associated with epigenetic modifications or mutations based oil the epigenetic or mutation status of chromatin in the subject, comprising using the methods of the invention.
• Another aspect of the invention relates to a method for identifying a biomarker of a disease or disorder associated with epigenetic modifications or mutations based on the epigenetic or mutation status of chromatin in a subject, comprising using the methods of the invention.
• An additional aspect of the invention relates to a method for screening for an agent that modifies the epigenetic or mutation status of chromatin in a subject, comprising using the methods of the invention.
• a further aspect of the invention relates to a method for assaying chromatin for a histone post-translational modification, mutation, and/or histone variant and/or a DNA post- transcriptional modification, wherein the improvement is the use of the nucleosome, panel, polynucleosome, array, pool, or bead of the invention in the assay as a spike-in control.
• Another aspect of the invention relates to a method for assaying binding of a factor to chromatin, wherein the improvement is the use of the nucleosome, panel, polynucleosome, array, pool, or bead of the invention in the assay as a spike-in control.
• FIG. 1 shows a schematic of chromatin accessibility assays (top) and chromatin mapping assays (bottom) using DNA-barcoded nucleosome spike-in controls.
• FIGS. 2A-2E show (FIGS. 2A-2B) DNA template design for DNA-barcoded nucleosome spike-ins.
• FIG. 2C Summary of spike-in panel, comprising unmodified, H3K4mel, H3K4me2, and H3K4me3 nucleosomes, and expected results using a highly specific antibody to H3K4me3.
• FIG. 2D Sequencing reads of nucleosome spike-in barcodes following CUT&RUN workflow using 500,000 K562 cells.
• FIG. 2E SNAP-ChIP specificity data using the same H3K4me3 antibody analyzed in (FIG. 2D).
• Nucleotide sequences are presented herein by single strand only, in the 5' to 3' direction, from left to right, unless specifically indicated otherwise. Nucleotides and amino acids are represented herein in the manner recommended by the IUPAC-IUB Biochemical Nomenclature Commission, or (for amino acids) by either the one-letter code, or the three letter code, both in accordance with 37 C.F.R. ⁇ 1.822 and established usage.
• the term“about,” as used herein when referring to a measurable value such as an amount of a compound or agent of this invention, dose, time, temperature, and the like, is meant to encompass variations of + 10%, ⁇ 5%, ⁇ 1%, + 0.5%, or even + 0.1% of the specified amount.
• nucleic acid or protein means that the nucleic acid or protein does not contain any element other than the recited element(s) that significantly alters (e.g., more than about 1%, 5% or 10%) the function of interest of the nucleic acid or protein.
• polypeptide encompasses both peptides and proteins, unless indicated otherwise.
• A“nucleic acid” or“nucleotide sequence” is a sequence of nucleotide bases, and may be RNA, DNA or DNA-RNA hybrid sequences (including both naturally occurring and non-naturally occurring nucleotide), but is preferably either single or double stranded DNA sequences.
• an“isolated” nucleic acid or nucleotide sequence e.g., an“isolated
• DNA or an“isolated RNA” means a nucleic acid or nucleotide sequence separated or substantially free from at least some of the other components of the naturally occurring organism or virus, for example, the cell or viral structural components or other polypeptides or nucleic acids commonly found associated with the nucleic acid or nucleotide sequence.
• an“isolated” polypeptide means a polypeptide that is separated or substantially tree from at least some of the other components of the naturally occurring WO 2020/132388 PCT/US2019/067735 organism or virus, for example, the cell or viral structural components or other polypeptides or nucleic acids commonly found associated with the polypeptide.
• a first aspect of the invention relates to a nucleosome comprising:
• a a protein octamer, containing two copies each of histones H2A, H2B, H3, and H4, and optionally, linker histone HI;
• a DNA molecule comprising:
• a DNA barcode indicative of the identity and/or concentration of a nucleosome feature
• iii a nuclease or transposase recognition sequence
• nucleosome feature is none, one, or more of the histones comprising a post-translational modification or a mutation and/or a histone variant and/or the DNA molecule comprising a post-transcriptional modification.
• the nucleosome further comprises:
• binding member linked to the DNA molecule, wherein the binding member specifically binds to a binding partner.
• the DNA molecule comprises a linker between the nucleosome positioning sequence and the binding member that is about 10 to about 80 nucleotides in length, wherein the linker comprises the nuclease or transposase recognition sequence.
• the linker is about 15 to about 40 nucleotides in length, e.g., about 15 to about 30 nucleotides in length, e.g., about 10, 15, 20, 25, 30, 35, 40, 45, 50,
• the nuclease or transposase recognition sequence may be any nucleotide sequence that is preferably recognized by a nuclease or transposase. In some embodiments, the nuclease or transposase recognition sequence is recognized by an endodeoxyribonuclease.
• Suitable endodeoxyribonucleases include, without limitation, micrococcal nuclease, SI nuclease, mung bean nuclease, pancreatic DNase I, yeast HO or I-Scel endonuclease, a restriction endonuclease, or a homing endonuclease, and modified or enhanced versions thereof.
• the recognition sequence is an A/T-rich region.
• the nuclease or transposase recognition sequence is recognized by a transposase.
• Suitable transposases include, without limitation, Tn5, Mu, IS5, IS91, Tn552, Tyl, Tn7, Tn/O, Mariner, P Element, Tn3, TnlO, or Tn903, and modified or enhanced versions thereof.
• the transposase is an enhanced Tn5.
• the recognition sequence is a G/C-rich region.
• the linker comprises both a nuclease recognition sequence (e.g., one or more patches of A/T rich sequences) and a transposase recognition sequence (e.g., one or more patches of G/C rich sequences) so that the nucleosomes of the invention can be used for multiple methods.
• An A/T rich region or G/C rich region is one that contains more than 50%, A/T bases or G/C bases, respectively, e.g., more than 50%, 55%, 60%, 65%, 70%, 75%, or 80%.
• a binding member When a binding member is present, it may be one half of a binding pair that provides a specific binding interaction.
• a suitable binding member and its binding partner include, without limitation, biotin with avidin or streptavidin, a nanotag with streptavidin, glutathione with glutathione transferase, an antigen/epitope with an antibody, polyhistidine with nickel, a polynucleotide with a complementary polynucleotide, an aptamer with its specific target molecule, or Si-tag and silica.
• the binding member may be linked to the DNA molecule at any position where the binding member is exposed for access by the binding partner. In some embodiments, the binding member is linked to the 5’ end of the DNA molecule. In some embodiments, the binding member is linked to the 3’ end of the DNA molecule.
• the DNA barcode may be any length and sequence that is suitable to uniquely identify the nucleosome and the feature associated with the nucleosome.
• DNA barcodes may be used to denote any type of unique feature of the DNA-barcoded nucleosome, including modification type (e.g. DNA methylation, histone methylation, histone variants, etc.), replicate number (e.g., technical replicates), or concentration.
• modification type e.g. DNA methylation, histone methylation, histone variants, etc.
• replicate number e.g., technical replicates
• concentration e.g., concentration.
• the DNA barcode has a length of about 6 to about 50 basepairs, e.g., about 7 to about 30 basepairs, e.g, about 8 to about 20 basepairs, e.g., about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
• Each of the histones in the nucleosome is independently fully synthetic, semisynthetic, or recombinant. Methods of producing histones synthetically, semi-synthetically, or recombinantly are well known in the art.
• the histone PTM may be any PTM for which measurement is desirable.
• the histone PTM is, without limitation, N-acetylation of serine and alanine; phosphorylation of serine, threonine and tyrosine; N-crotonylation, N-acylation of lysine; N6- methylation, N6,N6-dimethylation, N6,N6,N6-trimethylation of lysine; omega-N- methylation, symmetrical-dimethylation, asymmetrical-dimethylation of arginine;
• citrullination of arginine citrullination of arginine; ubiquitinylation of lysine; sumoylation of lysine; O-methylation of serine and threonine, ADP-ribosylation of arginine, aspartic acid and glutamic acid, or any combination thereof.
• the histone mutation may be any mutation known in the art or any mutation of interest.
• the histone mutations are oncogenic mutations, e.g., mutations associated with one or more types of cancer.
• Known oncogenic histone mutations include, without limitation, H3K4M, H3K9M, H3K27M, H3G34R, H3G34V, H3G34W,
• H3K36M H3K36M, or any combination thereof.
• Histone variants include, without limitation, H3.3, H2A.Bbd, H2A.Z.1, H2A.Z.2, H2A.X, mH2Al.l, mH2A1.2, mH2A2,
• the DNA post-transcriptional modification may be any modification for which measurement is desirable.
• the DNA post-transcriptional modification is 5-methylcytosine, 5-hydroxymethylcytosine, 5-formylcytosine, 5-carboxylcytosine, 3- methylcytosine, or any combination thereof.
• the invention further relates to a panel of the nucleosomes of the invention, wherein the panel comprises at least two nucleosomes comprising different nucleosome features.
• each nucleosome in the panel may be represented by a unique DNA barcode.
• the panel comprises, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 21, 25, 30, 35, or 40 or more nucleosomes comprising different nucleosome features or any range therein.
• each nucleosome comprising a different nucleosome feature is present at the same concentration in the panel.
• each nucleosome comprising a different nucleosome feature is present at multiple concentrations in the panel and the DNA barcode of each nucleosome indicates the concentration at which the nucleosome is present in the panel.
• the panel further comprises a nucleosome which does not comprise a nucleosome feature, e.g.
• the panel may comprise nucleosomes having a desirable set of nucleosome features, e.g., all known methylation PTMs or all known acetylation PTMs.
• Another aspect of the invention relates to a polynucleosome comprising: WO 2020/132388 PCT/US2019/067735 a. two or more protein octamers, each containing two copies each of histones H2A, H2B, H3, and H4, and optionally, linker histone HI ; and
• a DNA molecule comprising:
• a DNA barcode indicative of the identity and/or concentration of a nucleosome feature
• iii a nuclease or transposase recognition sequence
• nucleosome feature is none, one, or more of the histones comprising a post-translational modification or a mutation and/or a histone variant and/or the DNA molecule comprising a post-transcriptional modification.
• the polynucleosome further comprises:
• binding member linked to the DNA molecule, wherein the binding member specifically binds to a binding partner.
• the polynucleosome comprises 2-10 nucleosomes, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosomes or any range therein.
• the polynucleosome may comprise any of the embodiments of linker, nuclease or transposase recognition sequence, binding member and binding partner, DNA barcode, and nucleosome feature as described above for nucleosomes.
• Each histone in the polynucleosome is independently fully synthetic, semi-synthetic, or recombinant.
• An additional aspect of the invention relates to an array comprising the
• the nucleosome array can contain a single nucleosome feature (e.g. histone PTM, DNA modification, histone mutation, etc.) or be comprised of an ensemble of different features.
• DNA barcodes on the array can be used to denote the entire array or unique features within the array.
• a further aspect of the invention relates to a pool of the array of the invention, wherein each array comprises a nucleosome feature.
• the nucleosome array panel comprises, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 21, 25, 30, 35, or 40 or more nucleosome arrays comprising different nucleosome features or any range therein.
• each nucleosome array comprising a different nucleosome feature is present at the same concentration in the panel.
• each nucleosome array comprising a different nucleosome feature is present at multiple concentrations in the panel and the DNA barcode of each nucleosome indicates the concentration at which the nucleosome is present in the panel.
• the panel further comprises a WO 2020/132388 PCT/US2019/067735 nucleosome array, which does not comprise a nucleosome feature, e.g. , has no PTM or other modification, e.g. , for use as a control.
• a solid support e.g., a bead
• a solid support comprising a binding partner to the binding member of the nucleosome, panel, polynucleosome, array, or pool of the invention, wherein the bead is bound to the nucleosome, panel, polynucleosome, array, or pool.
• the bead may be any bead suitable for separating a cell, nucleus, organelle, or tissue from a sample and/or to attach the cell, nucleus, organelle, or tissue to a solid support.
• the bead may be composed of natural materials (e.g. , alginate) or synthetic materials (e.g. , polystyrene).
• the bead is a magnetic bead that can be separated by exposure to a magnetic field.
• kits comprising the nucleosome, panel, polynucleosome, array, pool, or bead of the invention.
• the kit may further comprise an antibody, aptamer, or other recognition agent that specifically binds to a nucleosome feature.
• the kit may further comprise a nuclease or transposase linked to an antibody-binding protein or to an entity that binds the recognition agent.
• the antibody-binding protein may be, without limitation, protein A, protein G, a fusion between protein A and protein G, protein L, or protein Y.
• the entity that binds the recognition agent is a protein.
• the kit may further comprise a nuclease or transposase that is not linked to an antibody-binding protein or to an entity that binds the recognition agent.
• the kit may further comprise a bead comprising a binding partner to the binding member, e.g, a magnetic bead.
• the kit may further comprise reagents and/or containers for carrying out the methods of the invention, e.g., buffers, enzymes (e.g., nucleases, transposases), detection agents, etc.
• the kit may further comprise instructions for carrying out the methods of the invention.
• nucleosomes and polynucleosomes of the invention may be used as spike-in controls in any chromatin assay known in the art in which an improved control/calibrator would be useful. Examples include, without limitation, the CUT&RUN assay (WO
• the DNA-barcoded nucleosome, panel, polynucleosome, array, or pool may be used as a spike-in to chromatin accessibility assays at a single concentration or a range of concentrations, wherein each concentration is represented by one WO 2020/132388 PCT/US2019/067735 or more nucleosome.
• the DNA-barcoded nucleosome, panel, polynucleosome, array, or pool may be used for assay optimization and/or quantitative crosssample comparisons.
• these assays include ATAC-seq and may be performed in bulk (i.e., multiple cells) or on a single cell.
• these assays can be performed in whole cells or extracted nuclei that are permeabilized. In some embodiments, assays are performed on a solid support. In some embodiments, quantitative recovery of spike-in reads can be used to normalize two or more samples. Further, this quantitative comparison of two or more biological samples genome-wide or at a specific loci can be used to test the utility of a therapy, diagnose a disease, determine disease prognosis, or monitor patient response to drug treatment.
• the DNA-barcoded nucleosome, panel, polynucleosome, array, or pool may be used as a spike-in to immunotethering assays at a single concentration or a range of concentrations, wherein each concentration is represented by one or more nucleosome.
• the DNA-barcoded nucleosome, panel, polynucleosome, array, or pool may be used for antibody specificity testing, assay optimization, and/or quantitative cross-sample comparisons. In some embodiments, these assays include
• spike-ins contain a binding moiety to bind to a solid support. In some embodiments, spike-ins do not contain a binding moiety capable of binding a solid support. In some embodiments, quantitative recovery of spike-in reads can be used to normalize two or more samples. Further, this quantitative comparison of two or more biological samples genome-wide or at a specific loci can be used to test the utility of a therapy, diagnose a disease, determine disease prognosis, or monitor patient response to drug treatment.
• a further aspect of the invention relates to a method for chromatin mapping or determining chromatin accessibility, wherein the improvement is the use of the nucleosome, panel, polynucleosome, array, pool, or bead of the invention in the assay as a spike-in control.
• Another aspect of the invention relates to a method for mapping chromatin using tethered enzymes, comprising the steps of:
• nucleosome, panel, polynucleosome, array, or pool of the invention to the permeabilized cell, nucleus, organelle, or tissue of a); c) contacting the permeabilized cell, nucleus, organelle, or tissue of b) and the nucleosome, panel, polynucleosome, array, or pool of b) with an antibody, aptamer, or recognition agent that specifically binds to a nucleosome feature;
• nuclease or transposase allowing the nuclease or transposase to cleave and/or tag DNA in the cell, nucleus, organelle, or tissue and the nuclease or transposase recognition sequence in the nucleosome, panel, polynucleosome, array, or pool;
• nucleosome feature is none, one, or more of the histones comprising a post- translational modification or a mutation and/or a histone variant and/or the DNA molecule comprising a post-transcriptional modification.
• the nuclease or transposase of step (d) is inactive and step (e) comprises activating the nuclease or transposase, e.g., by adding an ion such as calcium or magnesium.
• Another aspect of the invention relates to a method for mapping chromatin using tethered enzymes, comprising the steps of:
• nuclease or transposase cleave and/or tag DNA in the cell, nucleus, organelle, tissue, or cell-free nucleosome and the nuclease or transposase recognition sequence in the nucleosome, panel, polynucleosome, array, or pool;
• nucleosome feature is none, one, or more of the histones comprising a post- translational modification or a mutation and/or a histone variant and/or the DNA molecule comprising a post-transcriptional modification.
• the nuclease or transposase of step (e) is inactive and step (f) comprises activating the nuclease or transposase, e.g., by adding an ion such as calcium or magnesium.
• identifying the cleaved and/or tagged DNA comprises subjecting the cleaved and/or tagged DNA to amplification and/or sequencing, e.g., by qPCR,
• the method further comprises determining the identity of the nucleosome, panel, polynucleosome, array, or pool based on the sequence of the DNA barcode in the cleaved and/or tagged DNA.
• the method further comprises optimizing the method based on the results detected with the nucleosome, panel, polynucleosome, array, or pool. For example, the recovery of on-target / off-target DNA-barcoded nucleosomes could be used to optimize enzyme concentration, enzyme activation time, cell-to-enzyme ratio, etc.
• the methods may be carried out using any suitable format that provides a solid support for the cell, nucleus, organelle, or tissue.
• the solid support is a bead, e.g, a magnetic bead.
• the solid support is a well of a plate, e.g.,
• An additional aspect of the invention relates to a method for determining chromatin accessibility, comprising the steps of:
• nucleosome, panel, polynucleosome, array, or pool of the invention to the permeabilized cell, nucleus, organelle, or tissue of a);
• the transposase of step (c) is inactive and step (d) comprises activating the nuclease or transposase, e.g., by adding an ion such as calcium or magnesium.
• An additional aspect of the invention relates to a method for determining chromatin accessibility, comprising the steps of: a) binding a cell, nucleus, organelle, tissue, or cell-free nucleosome to a solid support; b) permeabilizing the cell, nucleus, organelle, or tissue;
• transposase allowing the transposase to tag DNA in the cell, nucleus, organelle, tissue, or cell- free nucleosome and in the nucleosome, panel, polynucleosome, array, or pool; and f) identifying the tagged DNA;
• the transposase of step (d) is inactive and step (e) comprises activating the nuclease or transposase, e.g., by adding an ion such as calcium or magnesium.
• identifying the tagged DNA comprises subjecting the tagged DNA to amplification and/or sequencing, e.g., by qPCR, Next Generation Sequencing, or Nanostring.
• the method further comprises determining the identity of the nucleosome, panel, polynucleosome, array, or pool based on the sequence of the DNA barcode in the tagged DNA.
• the method further comprises optimizing the method based on the results detected with the nucleosome, panel, polynucleosome, array, or pool.
• the recovery of on-target / off-target DNA-barcoded nucleosome array panels could be used to optimize enzyme concentration, enzyme activation time, cell-to-enzyme ratio, etc.
• the cell, nucleus, organelle, or tissue is obtained from a biological sample.
• the biological sample used in the methods of the invention may be any suitable sample.
• the sample is comprised of cell-free nucleosomes obtained from bodily fluids, such as blood, serum, plasma, urine, saliva, semen, prostatic fluid, nipple aspirate fluid, lachrymal fluid, perspiration, feces, cheek swabs, cerebrospinal fluid, cell lysate samples, amniotic fluid, gastrointestinal fluid, biopsy tissue, lymphatic fluid, or cerebrospinal fluid.
• bodily fluids such as blood, serum, plasma, urine, saliva, semen, prostatic fluid, nipple aspirate fluid, lachrymal fluid, perspiration, feces, cheek swabs, cerebrospinal fluid, cell lysate samples, amniotic fluid, gastrointestinal fluid, biopsy tissue, lymphatic fluid, or cerebrospinal fluid.
• Assays on cell-free nucleosomes may be performed by capturing sample nucleosomes onto a solid support.
• the cell-free nucleosomes may be captured using a general nucleosome binding agent (e.g., an agent that binds to an unmodified region of the nucleosome, such as the C-terminus of histone H3 or the‘acid patch’ found at the interface of histone H2A and histone H2B).
• a general nucleosome binding agent e.g., an agent that binds to an unmodified region of the nucleosome, such as the C-terminus of histone H3 or the‘acid patch’ found at the interface of histone H2A and histone H2B.
• the cell-free nucleosomes may be captured using a binding agent that specifically binds a histone post-translational modification, histone mutation, histone variant, or DNA post- transcriptional modification, e.g., in order to amp combinatorial modifications.
• the captured cell-free nucleosomes can then be analyzed for chromatin accessibility or chromatin mapping using the methods described herein
• the methods may be carried out using any suitable format with or without a solid support for the cell, nucleus, organelle, or tissue.
• the solid support is a bead, e.g. , a magnetic bead.
• the solid support is a well of a plate, e.g. ,
• the antibody, aptamer, or recognition agent use in the methods of the invention may be any agent that specifically recognizes and binds to a target, e.g., an antigen.
• a target e.g., an antigen.
• the term “antibody” includes antigen-binding fragments thereof, such as scFv, Fab, Fv, Fab’, F(ab’)2 fragments, dAb, VHH, nanobodies, V(NAR) or minimal recognition units.
• a further aspect of the invention relates to a method for detecting and quantitating the presence of an epigenetic modification or mutation in chromatin, comprising using the methods of the invention.
• An antibody, aptamer, or recognition agent that specifically binds to the epigenetic modification or mutation may be used to detect and quantitate the modification or mutation.
• Another aspect of the invention relates to a method for determining and quantitating the epigenetic or mutation status of chromatin in a subject having a disease or disorder, comprising using the methods of the invention.
• An antibody, aptamer, or recognition agent that specifically binds to one or more epigenetic modifications or mutations that may be associated with the disease or disorder of the subject may be used to detect and quantitate the modifications or mutations.
• An additional aspect of the invention relates to a method for monitoring changes in epigenetic or mutation status of chromatin over time in a subject, comprising using the methods of the invention.
• This method may be used to determine if the epigenetic or mutation status is improving, stable, or worsening over time.
• the steps of the method may be repeated as many times as desired to monitor changes in the status of an epigenetic modification or mutation, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 50, or 100 or more times.
• the method may be repeated on a regular schedule (e.g., daily, weekly, monthly, yearly) or on an as needed basis.
• the method may be repeated, for example, before, during, and/or after therapeutic treatment of a subject; after diagnosis of a disease or disorder in a subject; as part of determining a diagnosis of a disease or disorder in a subject; after identification of a subject as being at risk for development of a disease or disorder; or any other situation where it is desirable to monitor possible changes in epigenetic modifications or mutations.
• a further aspect of the invention relates to a method for measuring on-target activity of an epigenetic-targeting drug, comprising using the methods of the invention.
• the methods may be carried out before, during, and/or after administration of an epigenetic-targeting drug to determine the capability of the drug to alter the epigenetic status of the subject.
• Another aspect of the invention relates to a method for monitoring the effectiveness of an epigenetic therapy or mutation therapy in a subject having a disease or disorder associated with epigenetic modifications or mutations, comprising using the methods of the invention.
• Epigenetic therapies are those designed to alter the epigenetic status of proteins (e.g ., histones) or DNA.
• One example of an epigenetic therapy includes lysine deacetylase inhibitors (formerly termed histone deacetylase inhibitors) (e.g. , vorinostat (suberoylanilide hydroxamic acid), CI-994 (tacedinaline), MS-275 (entinostat), BMP-210, M344, NVP-
• CBHA CBHA, PCI-24781, ITF2357, valproic acid, trichostatin A, and sodium butyrate
• CTCL cutaneous T-cell lymphoma
• lung, breast, pancreas, renal, and bladder cancers, melanoma, glioblastoma, leukemias, lymphomas, and multiple myeloma including lung, breast, pancreas, renal, and bladder cancers, melanoma, glioblastoma, leukemias, lymphomas, and multiple myeloma.
• histone acetyltransferase inhibitors e.g., epigallocatechin-3- gallate, garcinol, anacardic acid, CPTH2, curcumin, MB-3, MG149, C646, and romidepsin.
• DNA methyltransferase inhibitors e.g, azacytidine, decitabine, zebularine, caffeic acid, chlorogenic acid, epigallocatechin, hydralazine, procainamide, procaine, and RG108
• Other epigenetic therapies include, without limitation, lysine methyltransferases (e.g., pinometostat, tazometostat, CPI-
• lysine demethylases e.g. , ORY 1001
• arginine methyltransferases e.g. , EPZ020411
• arginine deiminases e.g, GSK484
• isocitrate dehydrogenases e.g, enasidenib, ivosidenib.
• Mutation therapies include treatments designed to alter the nucleotide sequence of a gene (e.g ., encoding a histone). Examples include, without limitation, gene therapy.
• the steps of the method may be repeated as many times as desired to monitor effectiveness of the treatment, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 50, or 100 or more times.
• the method may be repeated on a regular schedule (e.g. , daily, weekly, monthly, yearly) or on as needed basis, e.g., until the therapeutic treatment is ended.
• the method may be repeated, for example, before, during, and/or after therapeutic treatment of a subject, e.g., after each administration of the treatment.
• the treatment is continued until the method of the invention shows that the treatment has been effective.
• An additional aspect of the invention relates to a method for selecting a suitable treatment for a subject having a disease or disorder associated with epigenetic modifications or mutations based on the epigenetic or mutation status of chromatin in the subject, comprising using the methods of the invention.
• the method may be applied, for example, to subjects that have been diagnosed or are suspected of having a disease or disorder associated with epigenetic modifications or mutations.
• a determination of the epigenetic status or mutation status of an epitope may indicate that the status of an epitope has been modified and an epigenetic therapy or mutation therapy should be administered to the subject to correct the modification.
• a determination that the status of an epitope has not been modified would indicate that an epigenetic therapy or mutation therapy would not be expected to be effective and should be avoided.
• a determination that a particular genomic locus has been deacetylated may indicate that treatment with a histone deacetylase inhibitor would be appropriate.
• a determination that a particular genomic locus has been hypermethylated may indicate that treatment with a DNA methyltransferase inhibitor would be appropriate.
• a further aspect of the invention relates to a method for determining a prognosis for a subject having a disease or disorder associated with epigenetic modifications or mutations based on the epigenetic or mutation status of chromatin in the subject, comprising using the methods of the invention.
• the epigenetic status or mutational status of an epitope is indicative of the prognosis of a disease or disorder associated with epigenetic modifications or mutations.
• a determination of the epigenetic status or mutational status of an epitope in a subj ect that has been diagnosed with or is suspected of having a disease or disorder associated with epigenetic modifications or mutations may be useful to determine the prognosis for the subject. Many such examples are known in the art.
• prostate cancer and hypermethylation of the glutathione-S transferase PI (GSTP1) gene promoter, the adenomatous polyposis coli (APC) gene, the genes PITX2, Clorfl 14, and GABRE ⁇ miR-452 ⁇ miR-224, as well as the three-gene marker panel
• Another example is prostate cancer and histone PTMs, including, without limitation, increased H3K18Acetylation and H3K4diMethylation associated with a significantly higher risk of prostate tumor recurrence, H4K 12 Acetylation and H4R3diMethylation correlated with tumor stage, and H3K9diMethylation associated with low-grade prostate cancer patients at risk for tumor recurrence.
• Another example is the link between overall survival in breast cancer patients and methylation status of CpGs in the genes CREB5, EXPH5, ZNF775, ADCY3, and ADMA8.
• Another example is glioblastoma and hypermethylation of intronic regions of genes like EGFR, PTEN, NF1, PIK3R1, RBI, PDGFRA, and QKI.
• a further example is inferior prognosis for colon cancer and methylation status of the promoter of the CNRIP1, FBN1, INA, MAL, SNCA, and SPG20 genes.
• Another aspect of the invention relates to a method for identifying a biomarker of a disease or disorder associated with epigenetic modifications or mutations based on the epigenetic or mutation status of chromatin in a subject, comprising using the methods of the invention.
• biological samples of diseased tissue may be taken from a number of patients have a disease or disorder and the epigenetic or mutation status of one or more epitopes determined. Correlations between the epitope status and the occurrence, stage, subtype, prognosis, etc., may then be identified using analytical techniques that are well known in the art.
• the disease or disorder associated with epigenetic modifications or mutations may be a cancer, a central nervous system (CNS) disorder, an autoimmune disorder, an inflammatory disorder, or an infectious disease.
• CNS central nervous system
• the cancer may be any benign or malignant abnormal growth of cells, including but not limited to acoustic neuroma, acute granulocytic leukemia, acute lymphocytic leukemia, acute myelogenous leukemia, adenocarcinoma, adrenal carcinoma, adrenal cortex carcinoma, anal cancer, anaplastic astrocytoma, angiosarcoma, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical carcinoma, cervical hyperplasia, chordoma, choriocarcinoma, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenosarcoma, embryonic carcinoma, endometrium cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, esophageal carcinoma, essential thrombo
• oligodendroglioma oligodendroglioma, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenosarcoma, papillary sarcoma, pinealoma, polycythemia vera, primary brain carcinoma, primary macroglobulinemia, prostate cancer, rectal cancer, renal cell carcinoma,
• retinoblastoma retinoblastoma, rhabdomyosarcoma, sebaceous gland sarcoma, seminoma, skin cancer, small cell lung carcinoma, soft-tissue sarcoma, squamous cell carcinoma, stomach carcinoma, sweat gland carcinoma, synovioma, testicular carcinoma, throat cancer, thyroid carcinoma, and Wilms’ tumor.
• CNS disorders include genetic disorders, neurodegenerative disorders, psychiatric disorders, and tumors.
• Illustrative diseases of the CNS include, but are not limited to,
• Tay Sachs disease Lesch-Nyan disease, epilepsy, cerebral infarcts, psychiatric disorders including mood disorders (e.g . , depression, bipolar affective disorder, persistent affective disorder, secondary mood disorder, mania, manic psychosis,), schizophrenia, schizoaffective disorder, schizophreniform disorder, drug dependency (e.g., alcoholism and other substance dependencies), neuroses (e.g., anxiety, obsessional disorder, somatoform disorder, dissociative disorder, grief, post-partum depression), psychosis (e.g., hallucinations and delusions, psychosis not otherwise specified (Psychosis NOS),), dementia, aging, paranoia, attention deficit disorder, psychosexual disorders, sleeping disorders, pain disorders, eating or weight disorders (e.g., obesity, cachexia, anorexia nervosa, and bulemia), ophthalmic disorders involving the retina, posterior tract, and optic nerve (e.g, retinitis pigmentosa,
• Autoimmune and inflammatory diseases and disorders include, without limitation, myocarditis, postmyocardial infarction syndrome, postpericardiotomy syndrome, Subacute bacterial endocarditis, anti-glomerular basement membrane nephritis, interstitial cystitis, lupus nephritis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, antisynthetase syndrome, sinusitis, periodontitis, atherosclerosis, dermatitis, allergy, allergic rhinitis, allergic airway inflammation, chronic obstructive pulmonary disease, eosinophilic pneumonia, eosinophilic esophagitis, hypereosinophilic syndrome, graft-versus-host disease, atopic dermatitis, tuberculosis, asthma, chronic peptic ulcer, alopecia areata, autoimmune angioedema, autoimmune pro
• Ord's thyroiditis Graves’ disease, autoimmune oophoritis, endometriosis, autoimmune orchitis, Sjogren’s syndrome, autoimmune enteropathy, celiac disease, Crohn’s disease, irritable bowel syndrome, diverticulitis, microscopic colitis, ulcerative colitis,
• antiphospholipid syndrome aplastic anemia, autoimmune hemolytic anemia, autoimmune lymphoproliferative syndrome, autoimmune neutropenia, autoimmune thrombocytopenic purpura, cold agglutinin disease, essential mixed cryoglobulinemia, Evans syndrome, pernicious anemia, pure red cell aplasia, thrombocytopenia, adiposis dolorosa, adult-onset Still’s disease, ankylosing spondylitis, CREST syndrome, drug-induced lupus, enthesitis- related arthritis, eosinophilic fasciitis, Felty syndrome, IgG4-related disease, juvenile arthritis, Lyme disease (chronic), mixed connective tissue disease, palindromic rheumatism,
• Parry Romberg syndrome Parsonage-Turner syndrome, psoriatic arthritis, reactive arthritis, relapsing polychondritis, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schnitzler syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease, dermatomyositis, fibromyalgia, myositis, myasthenia gravis, neuromyotonia, paraneoplastic cerebellar degeneration, polymyositis, acute disseminated encephalomyelitis, acute motor axonal neuropathy, anti-N-methyl-D-aspartate receptor encephalitis, Balo WO 2020/132388 PCT/US2019/067735 concentric sclerosis, Bickerstaff s encephalitis, chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, Hashimoto’s
• granulomatosis with polyangiitis giant cell arteritis, granulomatosis with polyangiitis, IgA vasculitis, Kawasaki’s disease, leukocytoclastic vasculitis, lupus vasculitis, rheumatoid vasculitis, microscopic polyangiitis, polyarteritis nodosa, polymyalgia rheumatic, urticarial vasculitis, vasculitis, and primary immune deficiency.
• infectious diseases refers to any disease associated with infection by an infectious agent.
• infectious agents include, without limitation, viruses and microorganisms (e.g ., bacteria, parasites, protozoans, cryptosporidiums).
• Viruses include, without limitation, Hepadnaviridae including hepatitis A, B, C, D, E, F, G, etc. ;
• Flaviviridae including human hepatitis C virus (HCV), yellow fever virus and dengue viruses; Retro viridae including human immunodeficiency viruses (HIV) and human T lymphotropic viruses (HTLV1 and HTLV2); Herpesviridae including herpes simplex viruses (HSV-1 and HSV-2), Epstein Barr virus (EBV), cytomegalovirus, varicella-zoster virus (VZV), human herpes virus 6 (HHV-6) human herpes virus 8 (HHV-8), and herpes B virus;
• HCV hepatitis C virus
• Retro viridae including human immunodeficiency viruses (HIV) and human T lymphotropic viruses (HTLV1 and HTLV2)
• Herpesviridae including herpes simplex viruses (HSV-1 and HSV-2), Epstein Barr virus (EBV), cytomegalovirus, varicella-zoster virus (VZV), human herpes virus 6 (HHV-6) human herpe
• Papovaviridae including human papilloma viruses
• Rhabdoviridae including rabies virus
• Paramyxoviridae including respiratory syncytial virus
• Reo viridae including rotaviruses
• Bunyaviridae including hantaviruses; Filoviridae including Ebola virus; Adenoviridae;
• Parvoviridae including parvovirus B- 19; Arenaviridae including Lassa virus;
• Orthomyxoviridae including influenza viruses; Poxviridae including Orf virus, molluscum contageosum virus, smallpox virus and Monkey pox virus; Togaviridae including Venezuelan equine encephalitis virus; Coronaviridae including corona viruses such as the severe acute respiratory syndrome (SARS) virus; and Picornaviridae including polioviruses; rhinoviruses; orbiviruses; picodnaviruses; encephalomyocarditis virus (EMV); Parainfluenza viruses, adenoviruses, Coxsackieviruses, Echoviruses, Rubeola virus, Rubella virus, human papillomaviruses, Canine distemper virus, Canine contagious hepatitis virus, Feline calicivirus, Feline rhinotracheitis vims, TGE vims (swine), Foot and mouth disease vims, simian vims 5, human parainfluenza
• Pathogenic microorganisms include, but are not limited to, Rickettsia, Chlamydia,
• Chlamydophila Mycobacteria, Clostridia, Corynebacteria, Mycoplasma, Ureaplasma,
• Treponema Bacillus, Haemophilus, Moraxella, Vibrio, Staphylococcus spp., Streptococcus spp., Campylobacter spp., Borrelia spp., Leptospira spp., Erlichia spp., Klebsiella spp.,
• microorganisms include, but are not limited to, Helicobacter pylori, Chlamydia pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma pneumoniae, Staphylococcus aureus, Streptococcus pyogenes,
• Streptococcus pneumoniae Streptococcus viridans, Enterococcus faecalis, Neisseria meningitidis, Neisseria gonorrhoeae, Treponema pallidum, Bacillus anthracis, Salmonella typhi, Vibrio cholera, Pasteur ella pestis (Yersinia pestis), Pseudomonas aeruginosa,
• Campylobacter jejuni Clostridium difficile, Clostridium botulinum, Mycobacterium tuberculosis, Borrelia burgdorferi, Haemophilus ducreyi, Corynebacterium diphtheria,
• Bordetella pertussis Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenza, Listeria monocytogenes, Shigella flexneri, Anaplasma phagocytophilum, enterotoxic Escherichia coli, and Schistosoma haematobium.
• the disease or disorder includes, but is not limited to, obesity, diabetes, heart disease, autism, fragile X syndrome, ATR-X syndrome, Angelman syndrome,
• Prader-Willi syndrome Beckwith Wiedemann syndrome, Rett syndrome, Rubinstein-Taybi syndrome, Coffin-Lowry syndrome Immunodeficiency-centrometric instability-facial anomalies syndrome, a-thalassaemia, leukemia, Cornelia de Langue syndrome, Kabuki syndrome, progressive systemic sclerosis, and cardiac hypertrophy.
• An additional aspect of the invention relates to a method for screening for an agent that modifies the epigenetic or mutation status of chromatin in a subject, comprising using the methods of the invention.
• the screening method may be used to identify agents that increase or decrease chromatin accessibility or epigenetic modifications or mutations.
• the detected increase or decrease is statistically significant, e.g, at least p ⁇ 0.05, e.g., p ⁇ 0.01, 0.005, or 0.001.
• the detected increase or decrease is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more.
• Suitable test compounds include organic and inorganic molecules.
• Suitable organic molecules can include but are not limited to small molecules (compounds less than about 1000 Daltons), polypeptides (including enzymes, antibodies, and antibody fragments), carbohydrates, lipids, coenzymes, and nucleic acid molecules (including DNA, RNA, and chimeras and analogs thereof) and nucleotides and nucleotide analogs.
• the methods of the invention can be practiced to screen a compound library, e.g, a small molecule library, a combinatorial chemical compound library, a polypeptide library, a cDNA library, a library of antisense nucleic acids, and the like, or an arrayed collection of compounds such as polypeptide and nucleic acid arrays.
• a compound library e.g, a small molecule library, a combinatorial chemical compound library, a polypeptide library, a cDNA library, a library of antisense nucleic acids, and the like, or an arrayed collection of compounds such as polypeptide and nucleic acid arrays.
• Any suitable screening assay format may be used, e.g. , high throughput screening.
• the method may also be used to characterize agents that have been identified as an agent that modifies the epigenetic or mutation status of a specific genomic locus in chromatin. Characterization, e.g., preclinical characterization, may include, for example, determining effective concentrations, determining effective dosage schedules, and measuring pharmacokinetics and pharmacodynamics.
• a further aspect of the invention relates to a method for assaying nucleosome accessibility or chromatin for a histone post-translational modification, mutation, and/or histone variant and/or a DNA post-transcriptional modification, wherein the improvement is the use of the nucleosome, panel, polynucleosome, array, pool, or bead of the invention in the assay as a spike-in control.
• Another aspect of the invention relates to a method for assaying binding of a factor to chromatin, wherein the improvement is the use of the nucleosome, panel, polynucleosome, array, pool, or bead of the invention in the assay as a spike-in control.
• the factor is a chromatin reader, writer, or eraser.
• Example 1 Schematics of how DNA-barcoded nucleosomes can be used in chromatin accessibility and chromatin mapping assays.
• nucleosome spike-ins can also be used in similar workflows that don’t use a solid support.
• FIG. 1 an ATAC-seq workflow is shown, where nucleosome spike-ins can be added to samples (cells or nuclei) before or after samples are bound to the solid support.
• samples are permeabilized and incubated with Tn5 (loaded with adaptors compatible with Illumina sequencers), which binds to open chromatin.
• Tagmentation is initiated by the addition of magnesium, followed by DNA purification, PCR, and next-generation sequencing. Similar to sample chromatin, Tn5 will bind and tagment linker DNA on spike-in nucleosomes. DNA recovered from the spike-in nucleosome can be used for assay optimization, technical variability monitoring, and quantitative sample normalization for cross-sample comparisons.
• a sample chromatin Similar to sample chromatin, Tn5 will bind and tagment linker DNA on spike-in nucleosomes. DNA recovered from the spike-in nucleosome can be used for assay optimization, technical variability monitoring, and quantitative sample normalization for cross-sample comparisons.
• FIG. 1 a
• nucleosome spike-ins containing on-target and/or off-target nucleosomes
• samples cells or nuclei
• samples are permeabilized and incubated with antibody and pAG-MNase.
• pAG-MNase is then activated via the addition of calcium, followed by DNA purification, library preparation, and next-generation sequencing.
• DNA recovered from the spike-in nucleosome can be used for antibody specificity testing, assay optimization, technical variability monitoring, and quantitative sample normalization for cross-sample comparisons.
• a similar workflow can be used for CUT&Tag assays with a few modifications, including replacing pAG-MNase with pAG-Tn5, activating with magnesium instead of calcium, and replacing library prep with a PCR step to prepare tagmented DNA fragments for next-generation sequencing.
• nucleosome positioning sequences can be used as nucleosome positioning sequences to develop DNA-barcoded recombinant nucleosome spike-ins that are compatible with immunotethering approaches, such as CUT&RUN or CUT&Tag.
• immunotethering approaches such as CUT&RUN or CUT&Tag.
• two different DNA templates for nucleosome assembly are shown. Each template is derived from the Widom 601 sequence (Lowary and Widom 1998), and is modified to contain a 24bp barcode near the 147 bp 3’ end. A 5’ biotin and various linker lengths flanking the 147bp nucleosome positioning sequence were also added (FIGS. 2A-2B).
• Con A beads were supplemented with streptavidin-coated beads to capture biotinylated dNuc spike-ins; and, ii) nucleosome spike-in panel was added prior to binding cells to Con A beads. If spike-ins are performing optimally, selective enrichment of the H3K4me3 dNuc barcode sequence in the sequencing data would be expected (vs. DNA barcodes for the unmodified, H3K4mel, or H3K4me2 dNucs). For this experiment, ⁇ 500,000 K562 cells were used and the sample was sequenced on an Illumina MiniSeq (4 million paired-end reads). As expected, specific enrichment of H3K4me3 was observed (FIG.
• HDACs histone deacetylases
• Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin.”
• Enigenetics Chromatin 7P1 33. Ucar, D., E. J. Marquez, C. H. Chung, R. Marches, R. J. Rossi, A. Uyar, T. C. Wu, J. George,

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Analytical Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Physics & Mathematics (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Urology & Nephrology (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Biophysics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Cell Biology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Enzymes And Modification Thereof (AREA)
• Apparatus Associated With Microorganisms And Enzymes (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=71100573

Family Applications (1)

Country Status (7)

Cited By (3)

Families Citing this family (2)

Citations (3)

Family Cites Families (4)

• 2019
  • 2019-12-20 CN CN201980092668.4A patent/CN113508180A/zh active Pending
  • 2019-12-20 WO PCT/US2019/067735 patent/WO2020132388A1/en not_active Ceased
  • 2019-12-20 AU AU2019403351A patent/AU2019403351A1/en active Pending
  • 2019-12-20 EP EP19898873.5A patent/EP3899042A4/en active Pending
  • 2019-12-20 CA CA3124482A patent/CA3124482A1/en active Pending
  • 2019-12-20 JP JP2021536186A patent/JP2022515221A/ja active Pending
  • 2019-12-20 US US17/416,928 patent/US12460246B2/en active Active
• 2025
  • 2025-10-09 US US19/354,009 patent/US20260035731A1/en active Pending

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events